Register

Forgot your password?

Forgot your username?

Amarantus BioScience Holdings, Inc. HCID Member | Biotech Specialty Pharma

c/o Janssen Labs @ QB3, 953 Indiana Street c/o
San Francisco, CA 94107 USA
phone: (408) 737-2734
fax: (408) 852-4427
Symbol  AMBS
Exchange  OTC BB
Founded  2008
Employees  3
www.amarantustherapeutics.com
Research Sector Biotech Specialty Pharma
Summary Description Biotechnology company that develops modifying treatments to address cell death.
Management Gerald E. Commissiong, President and Chief Executive Officer; John W. Commissiong, PhD, Chief Scientific Officer; Robert Farrell, J.D., Chief Financial Officer; Charlotte Keywood, MD., Chief Medical Officer, Therapeutics Division; Marc E. Faerber, Corporate Controller and Vice President of Financial Operations; Kerry Segal, Head of Business Development; Tiffini Clark, Head of Operations and Regulatory Affairs; F. Randall Grimes, Head of Sponsored Research; Paul Jorgensen, Head of Diagnostics Product Development; Mark Wakefield, Head of Clinical Development
 
Ownership
Financials Mkt Cap :10


* numbers in thousands
 
 
KeywordsParkinsons Disease, PD, CNS, cell death, biotechnology, apoptosis, neurodegenerative diseases, cardiovascular diseases, cardiovascular, neurodegenerative, Parkinsons disease, Myocardial Infaraction

Comment | Modify profile |
Updated: Nov. 25, 2014

Description

Amarantus Biosciences Pioneering the development of a novel therapeutic protein that has neuron-protective properties - termed MANF - which has the potential to serve as a first-in-class treatment for neurological disorders that stops and/or reverses their debilitating effects. Importantly, MANF is also significantly cardiac-protective, providing Amarantus the ability to employ a two pronged drug development approach - a neurological disorder platform, and a heart disease platform. View the OneMedPlace Initiation Report of Amarantus.

Products / Services

The most advanced drug candidate, AMRS001, is a growth factor indicated for the treatment of Parkinsons Disease and Myocardial Infarction. Parkinsons Disease generates over $2B in sales annually, and in the United States PD affects more than 500,000 annually.


Technology / Differentiation

Discovered from Amarantus proprietary Discovery Engine for Secreted Proteins (DESP), AMRS001, also known as MANF, is a highly potent, neurotrophic factor currently in pre-clinical development for the treatment of Parkinsons disease. Coming after other selective neurotrophic factors such as GDNF, Neurturin, NGF, and others, the AMRS001 discovery protocols were designed to identify a molecule that would be highly selective for dopamine producing neurons of the Substantia Nigra. While the clinical efficacy and benefit of neurotrophic factors has been in doubt, AMRS001 represents a new family of neurotrophic factors with mechanisms of action fundamentally differentiated from its predecessors. AMRS001 is an endogenous, widely expressed and highly potent growth factor involved in the prevention of apoptosis. This type of cell death is associated with several devastating human diseases as well as injury related disorders. By inhibiting certain pro-apoptotic caspase enzymes , AMRS001 is highly indicated for the treatment of several poorly served medical markets, including PD and Myocardial Infarction.

Market / Customers

5.2 MM Americans with Alzheimer's Disease; 200k under 65 with younger-onset Alzheimer’s. By 2025, the number of people with Alzheimer’s expected to reach 7.1 MM. At least 500k people with PD and ~50k new cases annually. The U.S. is the leading PD market, exceeding $1 B.


Competitors / Substitutes / Alternatives

There are two broad categories of diagnostics for AD and PD being pursued – genetic and molecular (proteins/biomarkers). Both diagnostics utilize patient material obtained from tissue, blood, urine, saliva, or cerebral spinal fluid CSF. There are many companies worldwide pursuing AD and PD diagnostics but many biomarkers have proven to be unreliable thus far.

Strategy

Amarantus business strategy, is to discover clinically relevant secreted human proteins, each with the potential to address several critically important medical indications, using our Discovery Engine for Secreted Proteins and develop them in order to address significant patient needs.<\p>